Intellia reports positive Phase 3 HAELO data for lonvo-z; BLA submission expected H2 2026

Intellia Therapeutics, Inc.

Phase 3 HAELO trial met primary endpoint: lonvo-z reduced HAE attacks by 87% vs placebo (p<0.0001); mean monthly attack rate 0.26 vs 2.10.
62% of lonvo-z patients attack-free and therapy-free for 6-month efficacy period vs 11% placebo; all key secondary endpoints met (p<0.0001).
Cash, cash equivalents and marketable securities $628.4M as of June 30, 2026, after $195M public offering; funds operations at least into 2028.
Net loss $106.6M in Q2 2026 vs $101.3M in Q2 2025; R&D expenses $82.6M, G&A expenses $37.8M due to commercial buildout.
Enrollment reinitiated in nex-z Phase 3 trials; genomic analysis identified HLA allele linked to liver transaminase elevations; HLA genotyping to be provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.